AbCellera Biologics, Inc.

AbCellera Biologics, Inc. has seen a notable increase in stock performance, significantly outpacing the S&P 500. The company reported a substantial rise in net sales and has shown strong operational trends over the past two quarters, attracting considerable institutional interest despite a net loss. Year-to-date, its returns have been impressive.

AbCellera Biologics, Inc. has achieved a new 52-week high, reflecting significant growth over the past year. The company has outperformed the S&P 500, with a market capitalization of USD 991 million. Despite current losses, its price-to-book ratio suggests potential appeal in the biotechnology sector.

AbCellera Biologics, Inc. has achieved a new 52-week high, reflecting a significant increase from its previous low and an impressive one-year performance compared to the S&P 500. With a market capitalization of USD 991 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite being loss-making.

AbCellera Biologics, Inc. saw a notable stock decline today, reaching an intraday low. Despite this, the company has delivered impressive annual returns and significant net sales growth. However, it reported a half-year net loss, and its trading dynamics suggest volatility amid strong institutional interest.

AbCellera Biologics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 1,079 million, operates in the Pharmaceuticals & Biotechnology sector and currently reports a negative return on equity and no dividend yield.

AbCellera Biologics, Inc. has shown strong stock performance, with significant gains and an impressive annual return. The company reported a substantial increase in net sales and a decrease in raw material costs, although it continues to face challenges with a notable net loss. Institutional holdings indicate solid investor support.

AbCellera Biologics, Inc. has seen a notable increase in stock performance, significantly outperforming the S&P 500 over various timeframes. Despite recent gains, the company has struggled with negative results for the past ten quarters and has experienced considerable declines over the last three to five years.

AbCellera Biologics, Inc. has experienced a decline in stock price and significant challenges over the past year, with a return of -3.50%. The company's performance has been notably poor over three and five years, contrasting sharply with the S&P 500's gains, indicating a difficult market environment.

AbCellera Biologics, Inc. faced notable stock volatility on November 7, 2025, with a significant decline amid contrasting market performance. The company has struggled with negative results over the past ten quarters, low liquidity indicators, and a market capitalization of USD 1,246 million, classifying it as a small-cap entity.

AbCellera Biologics, Inc. faced a notable decline in stock value, contrasting with the broader market's performance. Despite recent setbacks and negative results over ten quarters, the company has shown strong year-over-year growth. Institutional investors maintain significant holdings, indicating ongoing confidence in its fundamentals amid current challenges.

AbCellera Biologics, Inc. saw a notable rise in stock performance on October 15, 2025, reaching an intraday high. Despite a strong annual return, the company has struggled with negative results over the past ten quarters and faces financial challenges, though institutional holdings have increased, reflecting investor confidence.

AbCellera Biologics, Inc. achieved a new 52-week high of USD 6.51 on October 8, 2025, reflecting significant growth from its previous low. The company has outperformed the S&P 500 over the past year, although it continues to report losses and has notable financial metrics indicating its market position.

AbCellera Biologics, Inc. achieved a new 52-week high of USD 6.41 on October 3, 2025, reflecting a strong performance over the past year. The company, with a market capitalization of USD 1,246 million, has outperformed the S&P 500, despite reporting losses and a negative return on equity.

AbCellera Biologics, Inc. achieved a new 52-week high of USD 5.97 on October 1, 2025, reflecting a significant increase from its previous low. The company has shown a 69.8% rise in stock price over the past year, despite being in a loss-making position and lacking dividends.

AbCellera Biologics, Inc. saw a notable rise in stock performance on September 30, 2025, with significant gains over the past week and month. Despite impressive annual returns, the company has faced challenges, including negative results for ten consecutive quarters and declining profits, alongside strong institutional investor confidence.

AbCellera Biologics, Inc. has demonstrated strong stock performance, significantly outperforming the S&P 500 over various timeframes. Despite facing challenges with negative results for the past ten quarters and concerning financial metrics, institutional holdings indicate confidence from larger investors, reflecting the company's complex market position.

AbCellera Biologics, Inc. has recently adjusted its market evaluation, with its stock priced at $4.51. Over the past year, the company has achieved a notable 64.6% return, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting both bullish and cautious sentiments.